PUBLISHER: Grand View Research | PRODUCT CODE: 1654444
PUBLISHER: Grand View Research | PRODUCT CODE: 1654444
The global circRNA synthesis market size is anticipated to reach USD 442.5 million by 2030 and grow at a CAGR of 15.88% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The circRNA synthesis industry is experiencing significant growth, driven by ongoing research and development efforts that highlight the therapeutic potential of circular RNAs. A recent comprehensive review published in Nature Reviews Genetics by Circio scientists underscores the unique properties of circRNAs, such as enhanced stability and superior immunological profiles, which make them promising candidates for various therapeutic applications, including infectious diseases, CAR-T therapy, and gene therapy. This publication not only emphasizes the current advancements in circRNA therapeutics but also identifies opportunities and challenges in the field, thereby encouraging further investment and exploration.
Strategic collaborations between companies are also propelling the market forward. For instance, in January 2024, Circio has partnered with 4basebio to develop and test synthetic circVec DNA vectors for genetic medicine and vaccines. This partnership aims to combine Circio's circVec circular RNA expression system with 4basebio's proprietary synthetic DNA formats and unique nanoparticle delivery platform, Hermes, to create a powerful therapeutic combination. Such alliances are instrumental in advancing the development of durable, repeat-dosable, non-viral platforms for future synthetic DNA gene therapies.
Innovations in circRNA production technologies are further driving market expansion. For instance, in August 2024, Abogen Biosciences, has announced the development of a highly efficient RNA circularization cis-splicing system, referred to as the Cis-System, which enables the production of circular RNA. This proprietary system not only holds global intellectual property rights but also offers improvements over existing methods, potentially enhancing the efficiency and scalability of circRNA production. Such technological advancements are crucial for the broader application of circRNA in therapeutics and vaccines, thereby fueling market growth.